Synonym
RBI-257 Maleate; RBI 257 Maleate; RBI257 Maleate; p-Iodo-U-101958 Maleate; p-Iodo U-101958 Maleate
IUPAC/Chemical Name
N-[1-[(4-Iodophenyl)methyl]piperidin-4-yl]-N-methyl-3-propan-2-yloxypyridin-2-amine Maleate
InChi Key
NIRRRTUKUHIOTQ-BTJKTKAUSA-N
InChi Code
InChI=1S/C21H28IN3O.C4H4O4/c1-16(2)26-20-5-4-12-23-21(20)24(3)19-10-13-25(14-11-19)15-17-6-8-18(22)9-7-17;5-3(6)1-2-4(7)8/h4-9,12,16,19H,10-11,13-15H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1-
SMILES Code
CC(OC1=CC=CN=C1N(C2CCN(CC3=CC=C(I)C=C3)CC2)C)C.O=C(O)/C=C\C(O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
RBI 257 is a potent dopamine D4 receptor antagonist (Ki = 0.3 nM) that is selective over D2L, D3, D2-like, and D1 receptors by 1,721-, 439-, 1,336-, and 8,576-fold, respectively.
In vitro activity:
To be determined
In vivo activity:
RBI-257 reversed the basolateral dopamine-induced depolarization in the cortical collecting duct of rabbits.
Reference: Am J Physiol Renal Physiol. 2001 Jul;281(1):F114-22. https://pubmed.ncbi.nlm.nih.gov/11399652/
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMSO |
30.0 |
51.60 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
581.45
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Saito O, Ando Y, Kusano E, Asano Y. Functional characterization of basolateral and luminal dopamine receptors in rabbit CCD. Am J Physiol Renal Physiol. 2001 Jul;281(1):F114-22. doi: 10.1152/ajprenal.2001.281.1.F114. PMID: 11399652.
2. Kula NS, Tarazi FI, Baldessarini RJ, Xu L, Bakthavachalam V, Pounds S, True CD. Neuropharmacological assessment of potential dopamine D4 receptor-selective radioligands. Eur J Pharmacol. 1999 Feb 12;367(1):139-42. doi: 10.1016/s0014-2999(98)00980-7. PMID: 10082277.
In vitro protocol:
To be determined
In vivo protocol:
1. Saito O, Ando Y, Kusano E, Asano Y. Functional characterization of basolateral and luminal dopamine receptors in rabbit CCD. Am J Physiol Renal Physiol. 2001 Jul;281(1):F114-22. doi: 10.1152/ajprenal.2001.281.1.F114. PMID: 11399652.
2. Kula NS, Tarazi FI, Baldessarini RJ, Xu L, Bakthavachalam V, Pounds S, True CD. Neuropharmacological assessment of potential dopamine D4 receptor-selective radioligands. Eur J Pharmacol. 1999 Feb 12;367(1):139-42. doi: 10.1016/s0014-2999(98)00980-7. PMID: 10082277.
1: Kula NS, Baldessarini RJ, Kebabian JW, Bakthavachalam V, Xu L. RBI-257: a highly potent dopamine D4 receptor-selective ligand. Eur J Pharmacol. 1997 Jul 23;331(2-3):333-6. PubMed PMID: 9274997.
2: Cummings DF, Ericksen SS, Schetz JA. Three amino acids in the D2 dopamine receptor regulate selective ligand function and affinity. J Neurochem. 2009 Jul;110(1):45-57. doi: 10.1111/j.1471-4159.2009.06103.x. Epub 2009 Apr 16. PubMed PMID: 19486266; PubMed Central PMCID: PMC4896224.
3: Kula NS, Tarazi FI, Baldessarini RJ, Xu L, Bakthavachalam V, Pounds S, True CD. Neuropharmacological assessment of potential dopamine D4 receptor-selective radioligands. Eur J Pharmacol. 1999 Feb 12;367(1):139-42. PubMed PMID: 10082277.
4: Saito O, Ando Y, Kusano E, Asano Y. Functional characterization of basolateral and luminal dopamine receptors in rabbit CCD. Am J Physiol Renal Physiol. 2001 Jul;281(1):F114-22. PubMed PMID: 11399652.
5: Pedrosa R, Gomes P, Zeng C, Hopfer U, Jose PA, Soares-da-Silva P. Dopamine D3 receptor-mediated inhibition of Na+/H+ exchanger activity in normotensive and spontaneously hypertensive rat proximal tubular epithelial cells. Br J Pharmacol. 2004 Aug;142(8):1343-53. Epub 2004 Jul 20. PubMed PMID: 15265811; PubMed Central PMCID: PMC1575199.
6: Wilke RA, Hsu SF, Jackson MB. Dopamine D4 receptor mediated inhibition of potassium current in neurohypophysial nerve terminals. J Pharmacol Exp Ther. 1998 Feb;284(2):542-8. PubMed PMID: 9454795.
7: Depoortère R, Bardin L, Rodrigues M, Abrial E, Aliaga M, Newman-Tancredi A. Penile erection and yawning induced by dopamine D2-like receptor agonists in rats: influence of strain and contribution of dopamine D2, but not D3 and D4 receptors. Behav Pharmacol. 2009 Jul;20(4):303-11. doi: 10.1097/FBP.0b013e32832ec5aa. PubMed PMID: 19584712.
